Small intestine carcinoma
MONDO:0005522A carcinoma that arises from epithelial cells of the small intestine
Also known as: cancer of small bowel, cancer of the small bowel, small bowel cancer, small intestinal cancer, small intestine cancer, carcinoma of small bowel, carcinoma of small intestine, carcinoma of the small bowel
2962 clinical trials for this condition and its sub-types, 19 tagged with Small intestine carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Small intestine carcinoma
-
Carcinoma of duodenum 21 trials · 75 incl. sub-types
2 sub-types
- Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types Sub-types →
- Duodenal adenocarcinoma 9 trials · 44 incl. sub-types Sub-types →
-
Small intestine adenocarcinoma 18 trials · 60 incl. sub-types
2 sub-types
- Duodenal adenocarcinoma 9 trials · 44 incl. sub-types Sub-types →
- Jejunal adenocarcinoma 0 trials
-
1 sub-type
Most studied deeper sub-types
-
New triple therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
Disease control OngoingThis phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…
Phase 1 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for hard-to-treat cancers: targeted combo shows promise
Disease control OngoingThis study tests a new drug (JAB-21822) combined with cetuximab in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. Participants must have already tried at least one standard treatment. The goal is to see if the com…
Phase 1/2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New antibody IMT-009 tested in patients with advanced cancers
Disease control OngoingThis early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…
Phase 1/2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer-Fighting T-Cell therapy trial for GI cancers withdrawn before start
Disease control CancelledThis study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
FitBit and app aim to keep cancer surgery patients out of the hospital
Symptom relief OngoingThis study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …
Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC